Brentuximab Vedotin Articles & Analysis
3 articles found
AFM13 is a first-in-class tetravalent, bispecific NK cell engager that binds to CD30 on tumor cells and CD16A on NK cells. By engaging CD16-positive NK cells, AFM13 leads to NK cell-mediated killing of tumor cells.1 Pembrolizumab (Keytruda®) is approved in patients with R/R classical Hodgkin lymphoma as monotherapy. AFM13 showed single agent clinical activity with solid safety profile in a ...
As a result, Mylotarg was reapproved for marketing in 2017. Brentuximab Vedotin Brentuximab vedotin (Adcetris) was licensed in 2011 for the treatment of Hodgkin's lymphoma and mesenchymal large cell lymphoma, as well as other CD30-expressing lymphomas. ...
(deruxtecan) – cleavableunresectable or metastatic HER2+ BC5.4 mg/kg IV over 90 min, then 30 min, Q3WAstraZeneca/Daiichi Sankyo (2019) Padcev | Nectin-4(enfortumab vedotin)monomethyl auristatin E, cleavable linkeradvanced or metastatic urothelial cancer1.25 mpk IV over 30m Q1W, 3 wk of 28d cycleAstellas/Seattle Genetics (2019) Polivy | CD79(polatuzumab ...